₹1.77
+4.73% today
· 30d -8.29%
as of 2026-09-04
Price · Daily Candles
“MTEDUCare faces continued profit slide as revenue tumbles -42.21% YoY in Q4, trading near 52-week low.”
MTEDUCARE, a microcap stock at ₹12 Cr, continues to struggle with declining financial performance. The company reported a net loss of ₹-2.0 Cr for Q4 2025, with revenue collapsing -42.21% year-on-year to ₹7.0 Cr. Its ROCE stands at a substantial -4.0%, indicating significant capital inefficiency.
BULL CASE
+The stock is currently trading only 38.82% off its 52-week high, despite recent declines.
+The stock has seen a 1-month rally of +10.64% and a 3-month increase of +7.59%.
BEAR CASE
−Q4 2025 revenue dropped -42.21% YoY to ₹7.0 Cr, resulting in a net loss of ₹-2.0 Cr.
−Annual revenue for 2025 declined -17.67% YoY to ₹50.0 Cr, with the net profit at ₹-31.0 Cr.
−The 5-year revenue CAGR is significantly negative at -24.49%.
−Company is free cash flow negative with a FCF yield of -11.89%, and ROCE at -4.0%.
₹ Latest Earnings · Q ending 2026-03-31
REVENUE
₹10 Cr
-23.36% YoY
NET PROFIT
₹3 Cr
OPM
57.9%
+57.9pp YoY
EPS
₹0.36
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-50.0%, h2=-50.0%, h3=-50.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
MTEDUCARE's microcap valuation and -4.0% ROCE lag far behind peers like CRIZAC (ROCE 48.65%) and NIITMTS (ROCE 28.05%), despite some peers also lacking PE ratios.
PEERPEROCE %
MTEDUCARE—-4.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
49
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
NEUTRAL
40
Valuation
—
—
Growth
DECLINING
26
Profitability
DECENT
52
Technicals
WEAK
45
Risk
LOW
80
Key Stats
P/B
-2.08
52W HIGH
₹2.53
OFF HIGH
-30.04%
MKT CAP
₹13 Cr
◉ Active Signals
MACDBearish-0.0039
RSI(14)Neutral46.69
⧉ Strategy Fit 🔒